CervoMed Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 29, 2024. The company’s August 16, 2023 merger with EIP Pharma was accounted for as a reverse recapitalization, with EIP as accounting acquirer; accordingly, pre-merger comparative results reflect EIP’s historical business. Diffusion Pharmaceuticals changed its name to CervoMed at the merger.
Business context and financial results
CervoMed is a clinical-stage biotechnology company developing neflamapimod, an investigational oral drug, primarily for dementia with Lewy bodies (DLB). Its Phase 2b RewinD-LB trial is testing the drug in 160 patients with “pure DLB.” The company has no approved products and no product-sales revenue.
| Metric | 2023 | 2022 |
|---|---|---|
| Grant revenue | $7.14 million | None |
| Research and development expense | $8.44 million | $1.34 million |
| General and administrative expense | $6.52 million | $2.14 million |
| Loss from operations | $7.81 million | $3.48 million |
| Net loss | $2.17 million | $5.80 million |
| Cash used in operating activities | $7.45 million | $2.57 million |
The 2023 net loss was lower despite higher operating expenses, principally because of a $5.42 million noncash gain from remeasuring convertible notes before their conversion in the merger, compared with a $2.39 million noncash loss in 2022. These items materially affect the year-over-year net-loss comparison. No conventional gross margin is reported because the company has no product sales.
At December 31, 2023, cash and cash equivalents were $7.79 million, total current assets $9.96 million, total assets $9.97 million, total liabilities $2.60 million, and stockholders’ equity $7.38 million. The balance sheet showed no convertible notes remaining; they converted in connection with the merger. A previously available $2.5 million line of credit had no drawdowns and was terminated February 14, 2024. Accumulated deficit was $54.44 million.
Changes, liquidity, and financing
- R&D expense rose $7.10 million year over year, primarily as the DLB Phase 2b trial began. G&A rose $4.38 million, mainly from merger and public-company costs, including accounting and audit, insurance, staffing, and investor-relations expenses.
- Operating cash outflow increased to $7.45 million. Cash increased by $3.70 million overall, principally reflecting $11.15 million in financing cash flows associated with the reverse recapitalization and a common-stock sale.
- The $21 million National Institute on Aging (NIA) grant supports RewinD-LB. CervoMed recognized $7.14 million of grant revenue in 2023, received approximately $6.2 million in cash during the year, and reported a $0.92 million grant receivable. Grant disbursements are conditional and depend on costs, project progress, and government funding.
- Management and the auditor state that cash at year-end, together with expected remaining NIA grant funds, is insufficient to fund operations for at least 12 months after issuance of the financial statements without additional financing. The auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern.
- After year-end, on March 28, 2024, the company agreed to a private placement expected to close on or about April 1, subject to customary conditions. It was expected to provide approximately $50 million in upfront gross proceeds, before fees, and potentially up to $99.4 million more if Series A Warrants are exercised in full for cash. These expected proceeds are not included in the 2023 financial statements or stated cash-runway assessment. The warrants cover 2,532,285 shares at $39.24 per share.
Outlook, risks, and unusual items
- Management expected RewinD-LB enrollment to finish in Q2 2024 and initial results from its 16-week placebo-controlled portion in Q4 2024. It is targeting Phase 3 initiation in mid-2025, subject to trial results, funding, and regulatory discussions. FDA discussions provide a potential framework, not a guarantee of approval or of a single-trial pathway.
- Prior Phase 2a results showed statistically significant improvement versus placebo on dementia severity and mobility in the overall analysis; additional analyses suggested larger responses in pure DLB. The ongoing Phase 2b study is intended to confirm those findings. Early-stage and subgroup results may not predict later-trial outcomes.
- Neflamapimod has FDA Fast Track designation for DLB, but remains investigational. A partial FDA clinical hold limits U.S. dosing to no more than 40 mg three times daily for eligible patients; the company says this does not currently affect its planned program. Potential liver-enzyme elevations at substantially higher doses and long-term animal toxicology findings are disclosed safety considerations.
- Key risks include dependence on neflamapimod and successful clinical development; financing needs and potential dilution; grant-funding conditions; recruitment, manufacturing and third-party service-provider risks; regulatory uncertainty; and the absence of composition-of-matter patent protection for neflamapimod. The company also disclosed a long-running Paul Feller legal matter; it says it cannot predict the outcome or possible loss.
- Disclosure controls were deemed ineffective, with material weaknesses involving complex transactions and expense-account identification, evaluation, and recording. Management expected remediation efforts to continue during 2024. The independent auditor issued an unmodified opinion on the financial statements but did not attest to internal-control effectiveness.
- The company paused development of legacy Diffusion candidate TSC and is seeking a sale or license transaction. No such transaction is assured. In March 2024, the CFO began a temporary leave and the General Counsel was appointed Acting Principal Financial Officer.
Important facts for investors to verify
- Whether the 2024 private placement closed, the net proceeds received, and the resulting share and warrant dilution.
- Actual RewinD-LB enrollment timing, trial results, safety findings, and any changes to the expected Phase 3 plan or timeline.
- Receipt and timing of remaining NIA grant funds, including the requested $4 million supplement and later-year funding.
- Cash use, cash runway, and financing requirements after the private placement and through potential Phase 3 development.
- Progress in remediating the disclosed material weaknesses and whether future filings report effective controls.
- Developments in the Paul Feller proceeding, which was scheduled for October 23, 2024, and any material change in the company’s assessment.